$SLS News Article - SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Societ
https://marketwirenews.com/news-releases/sell...10269.html